Prozac (fluoxetine) and Zoloft (sertraline) are both selective serotonin reuptake inhibitors commonly prescribed for depression and anxiety, and both work well — but the most important difference between them has nothing to do with how well they treat symptoms. It is how long they stay in your system after you take them. Fluoxetine has a half-life measured in days to weeks, while sertraline clears in roughly a day, and that difference shapes everything from side effects to what happens when you reduce the dose or stop.
What does half-life mean, and why does it matter?
A medication's half-life is the time it takes for half of the drug to leave your bloodstream. A short half-life means the drug clears quickly; a long half-life means it lingers. That difference changes how stable the medication level stays between doses, how long it takes to reach steady state when you start, and what happens when you miss a dose or stop taking it.
According to the FDA label for Prozac, fluoxetine has an elimination half-life of one to three days after a single dose and four to six days after chronic use, and its active metabolite norfluoxetine has a half-life of four to sixteen days. That means fluoxetine and its metabolite stay active in your system for weeks after you stop taking it.
The FDA label for Zoloft reports that sertraline has an average terminal elimination half-life of about twenty-six hours — just over a day. Sertraline clears from your system much faster than fluoxetine does, and it does not have a long-acting metabolite.
The practical consequence: fluoxetine's gradual decline in blood levels after you stop makes discontinuation symptoms far less likely, while sertraline's faster clearance means withdrawal symptoms can appear more quickly if the medication is stopped abruptly.
How does the half-life difference affect coming off the medication?
This is where the half-life difference matters most. When you stop or reduce an antidepressant, some people experience discontinuation symptoms — dizziness, irritability, brain zaps, flu-like sensations — and the risk of those symptoms is closely tied to how fast the medication leaves your system.
A 2019 review in Deutsches Ärzteblatt International classified antidepressant withdrawal risk by half-life and found that fluoxetine is "particularly unproblematic, even in the case of abrupt discontinuation" because its especially long half-life means the drug tapers itself gradually as it clears (Henssler et al., 2019). Sertraline was classified as posing moderate withdrawal risk — lower than short-half-life medications like paroxetine, but higher than fluoxetine.
Both FDA labels recommend gradual dose reduction rather than abrupt cessation, but fluoxetine's pharmacology makes that recommendation less urgent — the medication's blood level declines slowly on its own, which may minimize discontinuation symptoms even without a formal taper. Sertraline, with its one-day half-life, requires more deliberate tapering if someone wants to stop or reduce the dose.
If someone has had discontinuation symptoms from a prior antidepressant or knows they are sensitive to medication changes, that difference becomes relevant to the choice. And if someone needs to switch medications, fluoxetine's lingering presence can complicate the timeline, because you need to wait weeks for it to clear before starting certain other medications to avoid interactions.
What are the FDA-approved uses for each medication?
Both medications are approved for major depressive disorder, but their indications diverge after that.
Prozac is FDA-approved for major depressive disorder in adults and children eight years and older, obsessive-compulsive disorder in adults and children, bulimia nervosa, and panic disorder (FDA label, Prozac).
Zoloft is FDA-approved for major depressive disorder in adults, obsessive-compulsive disorder in adults and children six years and older, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder (FDA label, Zoloft).
Sertraline has a broader set of FDA approvals, particularly for PTSD, social anxiety disorder, and premenstrual dysphoric disorder — conditions for which fluoxetine does not have formal approval. That does not mean fluoxetine never gets used for those conditions off-label, but it does mean the evidence base and regulatory support are stronger for sertraline in those diagnoses.
If the diagnosis is PTSD or social anxiety, sertraline may be the more evidence-backed starting point. If the diagnosis is major depression or generalized anxiety — for which both are approved — the choice comes down to other factors.
How do they compare in effectiveness?
Most direct comparison studies find that fluoxetine and sertraline have similar overall effectiveness for major depression. A 2023 study comparing fluoxetine, sertraline, and escitalopram in nearly six hundred adults with major depression found improvement rates above ninety percent for all three medications, with no statistically significant differences between them (Adjei et al., 2023). The study tracked psychological distress reduction over approximately one year, and the conclusion was that all three medications effectively improved outcomes.
Earlier research suggested that sertraline might have a modest advantage in people with severe depression, but those differences are small enough that they do not reliably predict what will work for a particular person. Individual response varies widely — someone who does not respond to one SSRI may respond well to another, and the reasons for that variability are not fully understood.
The takeaway is that effectiveness is similar enough that other factors — side effects, drug interactions, past medication history, and the half-life considerations discussed above — often drive the decision more than efficacy differences do.
What are the common side effects, and how do they differ?
Both fluoxetine and sertraline share the side-effect profile typical of SSRIs: nausea, headache, sleep changes, and sexual side effects are common across the class. But some patterns differ between the two.
According to the FDA label, fluoxetine is associated with higher rates of anxiety, nervousness, and insomnia — twelve to sixteen percent of people in major depression trials reported those symptoms, compared to seven to nine percent on placebo. Fluoxetine can be slightly activating for some people, which can be helpful if fatigue is a prominent symptom, but problematic if anxiety or insomnia is already an issue.
Sertraline's most distinctive side effect is gastrointestinal — particularly diarrhea — which is more common with sertraline than with most other SSRIs. That side effect often improves after the first few weeks as the body adjusts, but it can be troublesome enough that some people switch medications because of it.
Sexual side effects occur with both medications, though reported rates vary across studies. Weight changes, tremor, and sweating can occur with either medication, and individual responses are unpredictable enough that monitoring during the first few weeks is important regardless of which one is chosen.
How does a prescriber choose between them?
The choice is made during the evaluation, not from a checklist. A prescriber is looking at your current symptoms, past medication trials, other medications you are taking, medical history, and what side effects would be most disruptive for you — and those details shape the decision.
If you have had discontinuation symptoms from a prior antidepressant or are concerned about what happens if you need to stop, fluoxetine's long half-life and lower withdrawal risk might make it the safer starting point. If the diagnosis is PTSD, panic disorder, or social anxiety, sertraline's FDA approval for those conditions gives it an evidence advantage. If gastrointestinal side effects have been a problem with past medications, sertraline's higher rate of diarrhea might rule it out. If activation or insomnia is already an issue, fluoxetine's tendency to be slightly activating might be a reason to avoid it.
The evaluation is where those trade-offs get weighed, and the follow-up visits over the first two months determine whether the choice was the right one — or whether a dose adjustment or a switch is needed.
You can read more about how long antidepressants take to work and what to expect in the first weeks if you are weighing whether to start a medication.
What if the first medication does not work?
A first medication not working does not mean medication will not help. Roughly half of people do not respond adequately to their first antidepressant, and that is a common outcome rather than evidence that nothing will work. The next step might be a dose adjustment, a switch to a different medication, or an augmentation strategy — and those decisions are made during follow-up visits based on what happened during the trial.
If there was no effect at all, a switch to a medication with a different mechanism might make sense. If there was a partial response — some improvement but not enough — augmentation or a dose increase might be the better move. If side effects stopped the trial before it was complete, that is a different situation entirely. Those distinctions change the plan, which is why specificity about past medication trials matters during the evaluation.
Past trials are one of the most useful things you can bring to an evaluation, provided the details are clear: what was tried, at what dose range, for how long, and what exactly happened. "I tried Prozac and it did not work" is less useful than "I took fluoxetine for four weeks and stopped because I could not sleep, so it was never tested long enough to know whether it would have worked for the depression." The first version sounds like a failed trial; the second version says the medication was never actually tried at a therapeutic dose for a full duration.
For more on supervised tapering when a medication needs to be stopped or switched, NCNE's page on tapering off antidepressants describes the gradual reduction process.
Getting started
Laura Gabriel, PMHNP-BC, provides psychiatric evaluation and medication management for adults by telehealth video to people located in Connecticut, Massachusetts, New Hampshire, Maine, Rhode Island, Virginia, and Kentucky. The initial evaluation is where the choice between medications gets worked through — there is no obligation to start a medication at the first visit, and the conversation includes whether medication is the right step at all. Initial evaluations are typically $250–$350 before insurance reimbursement, and follow-up visits are $125–$200. You can learn more about how to get started as a new client or visit the insurance and cost page for details on coverage and self-pay rates.
References
Adjei, K., Adunlin, G., & Ali, A. A. (2023). Impact of sertraline, fluoxetine, and escitalopram on psychological distress among United States adult outpatients with a major depressive disorder. Healthcare (Basel), 11(5), 740. https://pmc.ncbi.nlm.nih.gov/articles/PMC10001334/
Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019). Antidepressant withdrawal and rebound phenomena. Deutsches Ärzteblatt International, 116(20), 355–361. https://pmc.ncbi.nlm.nih.gov/articles/PMC6637660/
U.S. Food and Drug Administration. (2023). PROZAC (fluoxetine hydrochloride) capsules, for oral use [Label]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b8fcce1-abfc-4631-9975-9d66e178dab6
U.S. Food and Drug Administration. (2023). ZOLOFT (sertraline hydrochloride) tablets, for oral use [Label]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3b0b1f8-abfd-4054-8645-fd076305f4f8